|
Description
Invasive cervical cancer accounts for 2.5 percent of all cancers that afflict women in the U.S. About 13,500 cases of invasive carcinoma of the cervix are diagnosed in the U.S. each year, while there are at least 50,000 new cases of a pre-invasive cancer, known as carcinoma in situ, where the cancer cells are confined to the surface skin of the cervix.
Since 1940, there has been a steady decrease in the incidence of carcinoma of the cervix because most women with no symptoms are screened with cervical and vaginal Pap smears. The probability at birth that a white woman will eventually develop cervical cancer dropped from 1.1 percent in 1975 to 0.7 percent in 1985. Similarly, for black women, the probability dropped from 2.3 percent in 1975 to 1.6 percent in 1985.
Over 90 percent of cervical carcinomas start in the surface cells lining the cervix and are called squamous cell carcinoma. About 5 to 9 percent start in glandular tissue and are called adenocarcinoma. Adenocarcinomas are more difficult to diagnose, but they are treated the same way as squamous cell carcinomas and the survival rate, stage for stage, is similar.
There are several types of adenocarcinoma. About 60 percent are the endocervical cell type, 10 percent are each endometrioid and clear cell carcinomas, and 20 percent are adenosquamous carcinoma.
There are two rare types of cervical carcinoma, known as small cell carcinoma and cervical sarcoma. Both have a poor prognosis.
Most scientists believe that cervical warts or pre-invasive cervical cancer may develop over a period of months or years after the cervix is infected with the human papilloma virus (HPV). This early tumor, known as mild dysplasia or cervical intraepithelial neoplasia (CIN-1) or Grade 1, can progress to moderate dysplasia (CIN-2), then to severe dysplasia and carcinoma in situ (CIN-3) and eventually to invasive carcinoma. Most physicians believe that about two-thirds of all cases of severe dysplasia will progress to invasive cancer if left untreated. This transformation takes anywhere from 3 to 30 years; about 10 years on the average.
Once the cervical cancer becomes invasive, it can spread locally to the upper vagina and into the tissues surrounding the upper vagina and the cervix (the parametrium). Eventually, it grows toward the pelvic sidewall, obstructing the tubes (ureters) that drain urine from the kidney to the bladder. It can also spread to the bladder and rectum.
Cervical tumor cells can invade the lymphatic system and spread to the lymph nodes in the pelvic wall. Eventually they may spread to the iliac lymph nodes higher in the pelvis, the aortic lymph nodes, the nodes above the collarbone and occasionally to the groin nodes.
Metastases can also spread through the bloodstream to the outer vagina, vulva, lungs, liver and brain. Invasion of the pelvic nerves is common in advanced cases. There may also be spread within the abdomen when the tumor penetrates the full thickness of the cervix.
There is much evidence that cervical carcinoma is related to sexually transmitted organisms.
Most researches believe that the human papilloma virus is either the cause or a strong cofactor in the development of pre-invasive and invasive carcinomas of the cervix, as well as pre-invasive and invasive squamous cell cancer of the vagina and vulva. Ninety to nintey-five percent of squamous cell carcinomas of the cervix contain the human papilloma virus DNA.
The virus is a sexually transmitted disease. There are more than 50 types of human papilloma virus (HPV) that infect humans. Types 6 and 11 usually cause warts, while types 16, 18, 31 and 33 usually result in high-grade cervical dysplasia (CIN-2 and CIN-3) and carcinomas. The virus infects the tissues of the lower genital tract and may produce obvious genital warts or mild, moderate or severe dysplasia and carcinoma in situ. Genital warts are associated with cervical, vaginal and vulvar dysplasia and invasive carcinoma (in 25 percent of all cases).
(Back to Top)
|